Results 41 to 50 of about 323,752 (284)
Evaluation of Angiogenesis Inhibitors Using the HUVEC Fibrin Bead Sprouting Assay
Bio-Protocol, 2016 Angiogenesis, the growth of new blood vessels from pre-existing vessels, is a critical process that occurs during normal development and tumor formation.
Laura Winters +3 more
doaj +1 more source
PDGFB as a vascular normalization agent in an ovarian cancer model treated with a gamma-secretase inhibitor [PDF]
, 2019 Ovarian cancer is the fifth leading cause of cancer-related deaths in women. In the past 20 years, the canonical types of drugs used to treat ovarian cancer have not been replaced and the survival rates have not changed.
Abramovich, Dalhia Nurit +7 more
core +1 more source
Medicine in Drug Discovery, 2019 New blood vessels formation from the existing vasculature is called angiogenesis. It is an essential physiological process for the growth of cells, tissue repair, wound healing, and reproductive system of females.
Siddharth J. Modi, Vithal M. Kulkarni
doaj +1 more source
Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions
FEBS Letters, EarlyView.Mutant p53 gain‐of‐function is thought to be mediated by interaction with other transcription factors. We identify multiple ETS transcription factors that can bind mutant p53 and found that this interaction can be promoted by a PXXPP motif. ETS proteins that strongly bound mutant p53 were upregulated in ovarian cancer compared to ETS proteins that ...
Stephanie A. Metcalf +6 more
wiley +1 more source
BMC Biotechnology, 2007 Background Angiogenesis assays are important tools for the identification of regulatory molecules and the potential development of therapeutic strategies to modulate neovascularization.
Desroches-Castan Agnès +5 more
doaj +1 more source
The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview
Medicina, 2022 Angiogenesis is the process of developing new blood vessels from pre-existing ones. This review summarizes the main features of physiological and pathological angiogenesis and those of angiogenesis activation and inhibition.
Cătălina Ionescu +7 more
doaj +1 more source
Circulating levels of matrix proteases and their inhibitors in pregnant women with and without a history of recurrent pregnancy loss [PDF]
, 2010 Background: We have recently shown that serum relaxin-2 levels are attenuated in women with a history of recurrent pregnancy loss (RPL). We sought to determine whether a history of RPL is also associated with changes in serum matrix metalloproteases ...
Anumba, D.O.C. +3 more
core +3 more sources
YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma
Molecular Oncology, EarlyView.The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy +9 more
wiley +1 more source
Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy [PDF]
, 2017 BACKGROUND: The angiogenesis in systemic sclerosis (SSc) is impaired. An imbalance of pro-angiogenic factors and angiogenesis inhibitors has been implicated in the progression of peripheral microvascular damage, defective vascular repair and fibrosis ...
Afeltra, Antonella M. Vittoria +7 more
core +1 more source
Molecular Oncology, EarlyView.This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert +13 more
wiley +1 more source